XML 11 R4.htm IDEA: XBRL DOCUMENT v2.3.0.15
STATEMENT OF STOCKHOLDERS' DEFICIT (USD $)
Total
Common Stock
Additional Paid-in Capital
Retained Deficit
Balance at Feb. 28, 2011$ (51,255)$ 131,449$ 94,260,707$ (94,443,411)
Balance (in shares) at Feb. 28, 2011 131,448,444  
Increase (Decrease) in Stockholders' Equity    
Cash contributed by S.R. Burzynski, M.D., Ph.D.276,904 276,904 
FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph.D.3,049,965 3,049,965 
Net loss(3,285,922)  (3,285,922)
Balance at Aug. 31, 2011$ (10,308)$ 131,449$ 97,587,576$ (97,729,333)
Balance (in shares) at Aug. 31, 2011 131,448,444